PDE10A-IN-2 hydrochloride

• CAT Number: I045426
• Molecular Formula: C33H38Cl3N5O
• Molecular Weight: 627.05
• Purity: ≥95%
• Synonyms: 8-[(E)-2-[5-methyl-1-[3-[3-(4-methylpiperazin-1-yl)propoxy]phenyl]benzimidazol-2-yl]ethenyl]quinoline;trihydrochloride
• InChI: InChI=1S/C33H35N5O.3ClH/c1-25-12-14-31-30(23-25)35-32(15-13-27-8-3-7-26-9-5-16-34-33(26)27)38(31)28-10-4-11-29(24-28)39-22-6-17-37-20-18-36(2)19-21-37;;;/h3-5,7-16,23-24H,6,17-22H2,1-2H3;3*1H/b15-13+
• InChIKey: NBTVSKHCPZVYQO-UWAJBHSPSA-N
• SMILES: CC1=CC2=C(C=C1)N(C(=N2)C=CC3=CC=CC4=C3N=CC=C4)C5=CC(=CC=C5)OCCCN6CCN(CC6)C.Cl.Cl.Cl

PDE10A-IN-2 hydrochloride (Cat No.: I045426) is a potent, selective inhibitor of phosphodiesterase 10A (PDE10A), an enzyme that hydrolyzes cyclic nucleotides cAMP and cGMP, predominantly expressed in the striatum of the brain. By blocking PDE10A activity, it increases intracellular cyclic nucleotide levels, modulating dopaminergic and glutamatergic neurotransmission. This compound is widely used in neuroscience research to investigate PDE10A’s role in psychiatric and neurodegenerative disorders, including schizophrenia, Huntington’s disease, and Parkinson’s disease, and to explore its potential as a therapeutic target for cognitive and motor function improvement.

Reference

[1]. Yuncong Yang, et al. Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension. Acta Pharm Sin B. 2020 De
[Content Brief]